Uncategorized - December 17, 2014
Intestinal Microbes Differ in Parkinson’s Patients
Parkinson’s disease sufferers have a different microbiota in their intestines than their healthy counterparts, according to a study conducted at the University of Helsinki and the Helsinki University Central Hospital. Researchers are now trying to determine what the connection between intestinal microbes and Parkinson’s disease is. “Our most important observation was that patients with Parkinson’s […]
Financing - December 16, 2014
BenGenBio Raises NOK90 Million
BerGenBio AS, a Norwegian biopharmaceutical company focused on developing medications for aggressive drug- resistant cancers, announced that it has raised NOK90 million (c. $15 million) in a private placing from new and existing investors. BerGenBio will use the proceeds from the financing to support the development of its pipeline of innovative cancer therapeutics, in particular an enlarged […]
Agreement - December 16, 2014
Firm to Market Blood Purification Therapy in Nordic Countries
CytoSorbents Corporation announced that it has entered into a multi-country strategic partnership with Fresenius Medical Care AG & CO KGaA to commercialize CytoSorbents’ CytoSorb® therapy in the Nordic countries. Under the terms of the agreement, Fresenius Medical Care will have the exclusive rights to distribute CytoSorb® for critical care applications in France, Poland, Sweden, […]
Uncategorized - December 16, 2014
Lipid May Predict Heart Disease
A team of scientists from Uppsala University, Karolinska Institutet and Colorado State University have identified novel lipid-derived molecules associated with future coronary heart disease events. The study published in the journal PLOS Genetics examined the metabolic profile of blood samples from more than 3,600 individuals who have been followed for as long as 10 years. […]
Collaboration - December 15, 2014
Genmab Earns Milestone Fee
Genmab A/S announced it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc., triggering a $3 million payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. “This milestone marks further progress in our DuoBody collaboration with Janssen. There are now 10 bispecific antibody programs […]
Economic Analysis - December 15, 2014
Expired Patents to Lower Sales
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expirations of several leading drugs, and AstraZeneca will be one of the hardest hit, according to research and consulting firm GlobalData. Besides AstraZeneca, the company’s report states that the drug makers hit hardest will include Otsuka and Eli […]
